Impact of health, treatment and psychological factors on cognitive functioning after chemotherapy for early breast cancer

Australian Psychologist

Volumn 44, Issue 4, 2009, Pages 235-247

  Vearncombe, Katharine Jean ^a,b   Pachana, Nancy A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WESLEY HOSPITAL   (Australia)

Author keywords

Cancer; Chemotherapy; Cognitive function; Neuropsychological assessment; Neurotoxicity; Oncology

Indexed keywords

EID: 84855663090     PISSN: 00050067     EISSN: 17429544     Source Type: Journal    
DOI: 10.1080/00050060903096652     Document Type: Article

References (64)

1. Ahles, T. A., & Saykin, A. J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews: Cancer, 7, 192-201.
2. Ahles, T. A., Saykin, A. J., McDonald, B. C., Furstenberg, C. T., Cole, B. F., Hanscom B. S. et al. (2008). Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Research and Treatment, 110, 143-152.
3. Amin, Z., Canli, T., & Epperson, C. N. (2005). Effect of estrogenserotonin interactions on mood and cognition. Behavioral and Cognitive Neuroscience Reviews, 4, 43-58.
4. Asthana, S. (2003) Estrogen and cognition: The story so far. Journal of Gerontology: Medical Sciences, 58A, 322-323.
5. Bachmann, G. A., & Leiblum, S. R. (2004). The impact of hormones on menopausal sexuality: A literature review. Menopause, 11, 120-130.
6. Bender, C. M., Paraska, K. K., Sereika, S. M., Ryan, C. M., & Berga, S. L. (2001). Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review. Journal of Pain and Symptom Management, 21, 407-424.
7. Bender, C. M., Sereika, S. M., Berga, S. L., Vogel, V. G., Brufsky, A. M., Paraska, K. K. et al. (2006). Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology, 15, 422-430.
8. Biringer, E., Mykletun, A., Dahl, A. A., Smith, A. D., Engedal, K., Nygaard, H. A. et al. (2005). The association between depression, anxiety, and cognitive function in the elderly general population: The Hordaland Health Study. International Journal of Geriatric Psychiatry, 20, 989-997.
9. Bierman, E. J. M., Comijs, H. C., Jonker, C., & Beekman, A. T. F. (2005). Effects of anxiety versus depression on cognition in later life. American Journal of Geriatric Psychiatry, 13, 686-693.
10. Brezden, C. B., Phillips, K. A., Abdolell, M., Bunston, T., & Tannock, I. F. (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 2695-2701.
11. Camilleri-Brennan, J., & Steele, R. J. C. (1999). Measurement of quality of life in surgery. Royal College of Surgeons of Edinburgh, 44(4), 253-259.
12. Capuron, L., Ravaud, A., & Dantzer, R. (2001). Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosomatic Medicine, 63, 376-386.
13. Castellon, S. A., Ganz, P. A., Bower, J. E., Petersen, L., Abraham, L., & Greendale, G. A. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and Tamoxifen. Journal of Clinical and Experimental Neuropsychology, 26, 955-969.
14. Cella, D. F., Lai, J., Chang, C., Peterman, A. H., & Slavin, M. (2002). Fatigue in cancer patients compared with fatigue in the general United States population. Cancer, 94, 528-538.
15. Cimprich, B. (1992). Attentional fatigue following breast cancer surgery. Research in Nursing and Health, 15, 199-207.
16. Collins, B., Mackenzie, J., Stewart, A., Bielajew, C., & Verma, S. (2009). Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology, 18, 134-143.
17. Dietrich, J., Han, R., Yang, Y., Mayer-Proschel, M., & Noble, M. (2006). CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. Journal of Biology, 5(7), 22.
18. Donovan, K., Small, B. J., Andrykowski, M. A., Schmitt, F. A., Munster, P., & Jacobsen, P. B. (2005). Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early stage breast carcinoma. Cancer, 104, 2499-2507.
19. Downie, F. P., Mar Fan, H. G., Houede-Tchen, N., Yi, Q., & Tannock, I. F. (2006). Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: Evaluation with patient interview after formal assessment. Psychooncology, 15, 921-930.
20. Falleti, M. G., Sanfilippo, A., Maruff, P., Weih, L., & Phillips, K. (2005). The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: A meta-analysis of the current literature. Brain and Cognition, 59, 60-70.
21. Han, R., Yang, Y. M., Dietrich, J., Luebke, A., Mayer-Proschel, M., & Noble, M. (2008). Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. Journal of Biology, 7(4), 12.
22. Hermelink, K., Henschel, V., Untch, M., Bauerfeind, I., Lux, M. P., & Munzel, K. (2008). Short term effects of treatmentinduced hormonal changes on cognitive function in breast cancer patients. Results of a multicenter, prospective, longitudinal study. Cancer, 113, 2431-2439.
23. Hermelink, K., Untuch, M., Lux, M. P., Kreienberg, R., Beck, T., Bauerfeind, I. et al. (2007). Cognitive function during neoadjuvant chemotherapy for breast cancer. Results of a prospective, multicenter, longitudinal study. Cancer, 109, 1905-1913.
24. Hess, L. M., & Insel, K. C. (2007). Chemotherapy-related change in cognitive function: A conceptual model. Oncology Nursing Forum, 34(5), 981-994.
25. Hurria, A., Rosen, C., Hudis, C., Zuckerman, E., Panageas, K. S., Lachs, M. S. et al. (2006). Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. Journal of the American Geriatrics Society, 54, 925-930.
26. Hurria, A., Somlo, G., & Ahles, T. (2007). Renaming "Chemobrain". Cancer Investigations, 25, 373-377.
27. Inagaki, M., Yoshikawa, E., Matsuoka, Y., Sugawara, Y., Nakano, T., Akechi, T. et al. (2007). Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer, 109, 146-156.
28. Jacobsen, P. B., Garland, L. L., Booth-Jones, M., Donovan, K. A., Thors, C. L., Winters, E. et al. (2004). Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. Journal of Pain and Symptom Management, 28, 7-18.
29. Jansen, C. E., Miaskowski, C., Dodd, M., Dowling, G., & Kramer, J. (2005). A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104, 2222-2233.
30. Jenkins, V., Shilling, V., Deutsch, D., Bloomfield, D., Morris, R., Allan, S. et al. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94, 828-834.
31. Joshi, G., Sultana, R., Tangpong, J., Cole, M. P., St Clair, D. K., Vore, M. et al. (2005). Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: Insight into chemobrain. Free Radical Research, 39, 1147-1154.
32. Kreukels, B. P. C., Schagen, S. B., Ridderinkhof, R., Boogerd, W., Hamburger, H. L., & van Dam, F. (2005). Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Research and Treatment, 94, 53-61.
33. Kurita, G. P., & de Mattes Pimenta, C. A. (2008). Cognitive impairment in cancer pain patients receiving opioids: A pilot study. Cancer Nursing, 31, 49-57.
34. Newman, G. C., Bang, H., Hussain, S. I., & Toole, J. (2007). Association of diabetes, homocysteine, and HDL with cognition and disability after stroke. Neurology, 69, 2054-2062.
35. Nys, G. M. S., Van Zandvoort, M. J. E., De Kort, P. L. M., Jansen, B. P. W., Van der Worp, H. B., Kappelle, L. J. et al. (2005). Domain-specific cognitive recovery after first-ever stroke: A follow-up of 11 cases. Journal of the International Neuropsychological Society, 11, 795-806.
36. Mar Fan, H. G., Houede-Tchen, N., Yi, Q., Chemerynsky, I., Downie, F., Sabate, K. et al. (2005). Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. Journal of Clinical Oncology, 23, 8025-8032.
37. Mehlsen, M., Pedersen, A. D., Jensen, A. B., & Zachariae, R. (2009). No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology, 18, 248-257.
38. Mehnert, A., Scherwath, A., Schirmer, L., Schleimer, B., Petersen, C., Schulz-Kindermann, F. et al. (2007). The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Education and Counseling, 66, 108-118.
39. O'Shaughnessy, J. A., Vukelja, S. J., Holmes, F. A., Savin, M., Jones, M., Royall, D. et al. (2005). Feasibility of quantifying the effects of epoetin alpha therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clinical Breast Cancer, 5, 439-446.
40. Quesnel, C., Savard, J., & Ivers, H. (2009). Cognitive impairments associated with breast cancer treatments: Results from a longitudinal study. Breast Cancer Research and Treatment, 116, 113-123.
41. Rogers, L. Q., Courneya, K. S., Robbins, K. T., Rao, K., Malone, J., Seiz, A. et al. (2008). Factors associated with fatigue, sleep and cognitive function among patients with head and neck cancers. Head and Neck, 30, 1310-1317.
42. Rugo, H. S., & Ahles, T. (2003). The impact of adjuvant therapy for breast cancer on cognitive function: Current evidence and directions for research. Seminars in Oncology, 30, 749-762.
43. Saykin, A. J., Ahles, T. A., & McDonald, B. C. (2003). Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological and neuroimaging perspectives. Seminars in Clinical Neuropsychiatry, 8, 201-216.
44. Saykin, A. J., Ahles, T. A., Schoenfeld, J. D., Wishart, H. A., Pietras, C. G., Furstenberg, C. T. et al. (2003). Gray matter reduction on voxel-based morphometry in chemotherapytreated cancer survivors. Journal of the International Neuropsychological Society, 9, 246.
45. Schagen, S. B., Hamburger, H. L., Muller, M. J., Boogerd, W., & van Dam, F. S. A.M. (2001). Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. Journal of Neurooncology, 51, 159-165.
46. Schagen, S. B., Muller, M. J., Boogerd, W., Mellenbergh, G. J., & van Dam, F. S. A M. (2006). Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. Journal of the National Cancer Institute, 98, 1742-1745.
47. Schagen, S. B., Muller, M.J., Boogerd, W., Rosenbrand, R. M., van Rhijn, D., Rodenhuis, S. et al. (2002). Late effects of adjuvant chemotherapy on cognitive function:Afollow-up study in breast cancer patients. Annals of Oncology, 13, 1387-1397.
48. Schagen, S. B., van Dam, F. S. A. M., Muller, M. J., Boorgerd, W., Lindeboom, J., & Bruning, P. F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85, 640-650.
49. Shilling, V., Jenkins, V., & Trapala, I. S. (2006). The (mis)-classification of chemo-fog: Methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Research and Treatment, 95, 125-129.
50. Silverman, D. H. S., Castellon, S. A., Abraham, L., Dy, C. J., Pio, B. S., Ganz, P. A. et al. (2003). Abnormal regional brain metabolism in breast cancer survivors after adjuvant chemotherapy is associated with cognitive change. Proceedings of the American Society for Clinical Oncology, 22, 12 (Abstract 47).
51. Silverman, D. H. S., Dy, C. J., Castellon, S. A., Lai, J., Pio, B. S., Abraham, L. et al. (2007). Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Research and Treatment, 103, 303-311.
52. Stewart, A., Bielajew, C., Collins, B., Parkinson, M., & Tomiak, E. (2006). A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clinical Neuropsychology 20, 76-89.
53. Stewart, A., Collins, B., Mackenzie, J., Tomiak, E., Verma, S., & Bielajew, C. (2008). The cognitive effects of adjuvant chemotherapy in early stage breast cancer: A prospective study. Psychooncology, 17, 122-130.
54. Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q., Hu, H., Chemerynsky, I. et al. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21(22), 4175-4183.
55. van Dam, F. S. A. M., Schagen, S., Muller, M. J., Boogerd, W., Wall, E., Fortuym, D. et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218.
56. Vardy, J., & Tannock, I. (2007). Cognitive function after chemotherapy in adults with solid tumours. Critical Reviews in Oncology/Hematology, 63, 183-202.
57. Vardy, J., Wefle, J. S., Ahles, T., Tannock, I. F., & Schagen, S. E. (2008). Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop. Annals of Oncology, 19, 623-629.
58. Verstappen, C. C. P., Heimans, J. J., Hoekman, K., & Postma, T. J. (2003). Neurotoxic complications of chemotherapy in patients with cancer. Clinical signs and optimal management. Drugs, 63(15), 1549-1563.
59. Wefel, J. S., Lenzi, R., Theriault, R., Buzdar, A. U., Cruickshank, S., & Meyers, C. A. (2004). 'Chemobrain' in breast carcinoma? A prologue. Cancer, 101, 466-475.
60. Wefel, J. S., Lenzi, R., Theriault, R. L., Davis, R. N., & Meyers, C. A. (2004). The cognitive sequelae of standarddose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer, 100, 2292-2299.
61. Wieneke, M. H., & Dienst, E. R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology, 4, 61-66.
62. Wilson, J., Yao, G. L., Raftery, J., Bohlius, J., Brunskill, S., Sandercock, J., et al. (2007). A systemic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technology Assessment, 11(13), 1-202.
63. Yoshikawa, E., Matsuoka, Y., Inagaki, M., Nakano, T., Akechi, T., Kobayakawa, M. et al. (2005). No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Research and Treatment, 92, 81-84.
64. Zec, R. F., & Trivedi, M. A. (2002). The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: A critical and theoretical review. Neuropsychological Review, 12(2), 65-109.